Pediatric Studies

Many studies of filgrastim administration after chemotherapy in children with acute leukemias or solid tumors have shown that the incidences of adverse events were similar in patients receiving placebo/no drug or filgrastim. In our own study of patients with high-risk acute lymphoblastic leukemia comparing 121 chemotherapy cycles plus filgrastim and 137 control chemotherapy cycles, only one World Health Organization grade III vasculitis was considered to be attributed to filgrastim (2). This topic is reviewed in Lerhrnbecher and Welte (14).

0 0

Post a comment